ReviewGels (Basel, Switzerland)2026
From Gelatin to GelMA: Versatility, Challenges, and Biomedical Applications of GelMA Hydrogels.
Review in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gelatin is a natural biopolymer derived from collagen and is widely employed in biomedical applications because of its biocompatibility, biodegradability, low toxicity, water solubility, and intrinsic thermo-responsive gelation behavior. Owing to the presence of bioactive motifs and its ability to form hydrogels under mild conditions, gelatin has emerged as a promising material for tissue engineering, drug delivery, and in vitro modeling. However, the poor mechanical stability and rapid dissolution of native gelatin under physiological conditions limit its direct use in advanced biomedical systems. To overcome these drawbacks, several chemical modification strategies have been developed, among which gelatin methacryloyl (GelMA) is one of the most investigated derivatives. GelMA combines the biological advantages of gelatin with photo-crosslinkable methacryloyl groups, enabling the fabrication of stable hydrogels with tunable mechanical, rheological, and degradation properties. This review adopts a source-to-performance perspective, systematically examining how gelatin origin, processing history, molecular characteristics, and Bloom strength may influence GelMA functionalization and subsequent hydrogel network formation. Particular attention is given to Type A and Type B gelatin, while recognizing that this classification does not fully capture the variability in the gelatin precursor. The review critically discusses how precursor characteristics interact with key synthesis and formulation parameters, including the degree of substitution/functionalization (DS/DoF), polymer concentration, photoinitiator content, and photo-crosslinking conditions, ultimately affecting network formation and the mechanical, rheological, swelling, porosity, degradation, and biological properties of GelMA hydrogels. This interconnected view highlights how variability introduced at the precursor level may propagate through functionalization and crosslinking, contributing to differences in GelMA performance and limiting direct comparison among reported formulations. The implications of these material-dependent properties are examined across three major biomedical application areas: tissue engineering, controlled drug delivery, and physiologically relevant three-dimensional in vitro models. Finally, current challenges and emerging opportunities related to GelMA standardization, biofabrication, multifunctional hydrogel design, personalized medicine, and clinical translation are considered. Overall, GelMA is presented not simply as a versatile biomaterial, but as a tunable protein-derived platform whose performance depends on the interconnected effects of precursor characteristics, functionalization, formulation, and network formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.